Tenaya Therapeutics Inc (TNYA) concluded trading on Thursday at a closing price of $0.87, with 4.73 million shares of worth about $4.11 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -39.43% during that period and on July 17, 2025 the price saw a gain of about 20.17%. Currently the company’s common shares owned by public are about 162.66M shares, out of which, 134.18M shares are available for trading.
Stock saw a price change of 25.92% in past 5 days and over the past one month there was a price change of 39.18%. Year-to-date (YTD), TNYA shares are showing a performance of -75.39% which decreased to -39.43% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.36 but also hit the highest price of $4.06 during that period. The average intraday trading volume for Tenaya Therapeutics Inc shares is 2.38 million. The stock is currently trading 32.69% above its 20-day simple moving average (SMA20), while that difference is up 54.53% for SMA50 and it goes to -29.64% lower than SMA200.
Tenaya Therapeutics Inc (NASDAQ: TNYA) currently have 162.66M outstanding shares and institutions hold larger chunk of about 27.53% of that.
The stock has a current market capitalization of $140.89M and its 3Y-monthly beta is at 3.01. It has posted earnings per share of -$1.16 in the same period. It has Quick Ratio of 6.68 while making debt-to-equity ratio of 0.11. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for TNYA, volatility over the week remained 10.32% while standing at 9.22% over the month.
Analysts are in expectations that Tenaya Therapeutics Inc (TNYA) stock would likely to be making an EPS of -0.18 in the current quarter, while forecast for next quarter EPS is -0.18 and it is -0.63 for next year. For the current quarter EPS, analysts have given the company a lowest target -0.26 which is -0.11 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -0.34 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 38.24% while it is estimated to increase by 12.72% in next year.
Coverage by Leerink Partners stated Tenaya Therapeutics Inc (TNYA) stock as an Outperform in their note to investors on November 30, 2023, suggesting a price target of $7 for the stock.
